Alamar Bio
The Future of Precision Proteomic Analysis
Alamar Biosciences is creating the most sensitive proteomics platform that can profile thousands of proteins simultaneously from as little as one microliter of plasma. Its fully automated, high-throughput precision proteomics platform will pave the way to discovering the deepest secrets of the proteome. It has the potential to fulfill the promise of the human plasma proteome to transform healthcare with a new wave of biomarkers for early detection and prevention of common diseases.
Cyted
Early Detection of Pre-Cancerous Esophageal Conditions
Esophageal adenocarcinoma (EA) prevalence has increased 6-fold in Western countries over the past 40 years; about half of patients die within a year of diagnosis. Detection of Barret’s esophagus, a pre-cancerous state, greatly increases chances of survival, but the current method is an invasive and expensive endoscopy.
Cyted is developing a simple molecular test for Barret’s that can be administered at home, eliminating the need for hospital-based surveillance that take half a day to administer and misses up to 90% of current sufferers.
Geneoscopy
Colorectal cancer is the second-leading cause of cancer deaths annually in the United States and early detection and treatment are key to improve survival. Geneoscopy is a clinical-stage diagnostics company focused on new methods for early detection of gastrointestinal diseases and cancer. Geneoscopy has developed a proprietary isolation and screening platform to assay RNA biomarkers from stool. This platform is non-invasive and can be used by patients at home.
The initial diagnostic focuses on early detection of colorectal neoplasms and advanced adenomas in average-risk individuals and was granted Breakthrough Device Designation by the US FDA in January 2020. Geneoscopy’s findings from its initial clinical study demonstrated 95% sensitivity with traditional colonoscopy-based screenings for detecting colorectal cancer.